GlassScriptPhysician profile
Rodina Vatanparast
NPI 1770887788
$3,289.95
in general payments reported to CMS, 2019-2025
20 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $80.51 · 2021: $11.92 · 2022: $37.34 · 2023: $171 · 2024: $1,697 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,575 · Food and Beverage: $405 · Education: $31.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,575.00 |
| Food and Beverage | $404.79 |
| Education | $31.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,667.93 | 2019-2024 | |
| Celgene Corporation | $253.94 | 2019 | |
| Pfizer INC. | $204.08 | 2019-2023 | |
| Amgen INC. | $185.02 | 2019 | |
| Sirtex Medical INC | $143.30 | 2025 | Sir-Spheres Microspheres |
| Genmab U.S., INC. | $139.76 | 2023 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $121.73 | 2024 | Libtayo |
| Eisai INC. | $120.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $86.40 | 2019 | |
| Merck Sharp & Dohme LLC | $86.16 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.35 | 2019 | |
| Astellas Pharma US INC | $41.11 | 2019 | |
| Abbvie INC. | $40.66 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.29 | 2019 | |
| Seagen INC. | $28.57 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $24.77 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $22.91 | 2019 | |
| Exelixis INC. | $19.99 | 2019 | |
| Genzyme Corporation | $12.90 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodina Vatanparast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.